Quantedge Capital’s Harmony Biosciences HRMY Stock Holding History

Quantedge Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$874K	Sell	24,000 -26,500	-52%	-$836K	0.66%	27
2026 Q1	$1.41M	Sell	50,500 -10,800	-18%	-$354K	0.77%	27
2025 Q4	$2.29M	Sell	61,300 -3,400	-5%	-$112K	1.09%	23
2025 Q3	$1.78M	Buy	+64,700	New	+$2.23M	0.98%	19
2023 Q2	–	Sell	-10,700	Closed	-$349K	–	147
2023 Q1	$349K	Sell	10,700 -25,200	-70%	-$1.15M	0.14%	102
2022 Q4	$1.98M	Buy	35,900 +2,900	+9%	+$159K	0.66%	48
2022 Q3	$1.46M	Buy	33,000 +5,500	+20%	+$268K	0.45%	70
2022 Q2	$1.34M	Buy	+27,500	New	+$1.24M	0.27%	104

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantedge Capital's HRMY Position: Q2 2026 in Review

Quantedge Capital reduced its Harmony Biosciences (HRMY) stake by 52% in Q2 2026, selling an estimated $836K and leaving 24,000 shares worth $874K. The position accounts for 0.66% of the portfolio, ranked #27.

Quantedge Capital first reported a position in HRMY in Q2 2022 and has held it in 8 quarters since. The position peaked at $2.29M in Q4 2025. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Quantedge Capital held 24,000 shares of Harmony Biosciences worth $874K as of Q2 2026.
Quantedge Capital sold 26,500 Harmony Biosciences shares in Q2 2026, an estimated $836K.
Harmony Biosciences made up 0.66% of Quantedge Capital's portfolio in Q2 2026, its #27 holding.
Quantedge Capital first reported a position in Harmony Biosciences in Q2 2022 and has held it in 8 quarters since.
Quantedge Capital's Harmony Biosciences position peaked at $2.29M in Q4 2025.
328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Quantedge Capital's 13F filing for Q2 2026, filed 6 Aug 2026.